2024-05-02 20:35:19 ET
Tandem Diabetes Care, Inc. (TNDM)
Q1 2024 Earnings Conference Call
May 02, 2024, 04:30 PM ET
Company Participants
Susan Morrison - Executive Vice President and Chief Administrative Officer.
John Sheridan - President and Chief Executive Officer
Leigh Vosseller - Executive Vice President and Chief Financial Officer
Conference Call Participants
Steve Lichtman - Oppenheimer
Brooks O'Neil - Lake Street Capital Markets
Mike Kratky - Leerink Partners
Mathew Blackman - Stifel
Chris Pasquale - Nephron Research
Matthew O'Brien - Piper
Larry Biegelsen - Wells Fargo
Danielle Antalffy - UBS
Matt Taylor - Jefferies
Jayson Bedford - Raymond James
Jeff Johnson - Baird
Josh Jennings - TD Cowen
Travis Steed - BoA
Michael Polark - Wolfe Research
Matt Miksic - Barclays
Presentation
Operator
Thank you for standing by. Welcome to Tandem Diabetes Care's First Quarter 2024 Earnings. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today's program is being recorded.
And now I'd like to introduce your host for today's program, Susan Morrison, EVP and Chief Administrative Officer. Please go ahead.
Susan Morrison
Hello, everyone, and thanks for joining Tandem's first quarter 2024 earnings call. As a reminder, today's discussion will include forward-looking statements. These statements reflect management's expectations about future events, our product pipeline, development time lines and financial performance and operating plans and speak only as of today's date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements. A list of factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is highlighted in our press release issued earlier today and under the Risk Factors portion and elsewhere in our most recent annual report on Form 10-K as updated by our most recent quarterly report on Form 10-Q. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or other factors.
Today's discussion will also include references to a number of GAAP and non-GAAP financial measures. Non-GAAP financial measures are provided to give our investors information that we believe is indicative of our core operating performance and reflects our ongoing business operations. We believe these non-GAAP financial measures facilitate better comparisons of operating results across reporting periods. Any non-GAAP information presented should not be considered as a substitution independently or superior to results prepared in accordance with GAAP. Please refer to our earnings release issued earlier today and available on the Investor Center portion of our website for a reconciliation of these measures to their most directly comparable GAAP financial measure.
Leading today's call is John Sheridan, Tandem's President and CEO, who will be joined by Leigh Vosseller, our Executive Vice President and Chief Financial Officer.
I'll now turn the call over to John.
John Sheridan
Thanks, Susan, and welcome, everyone, to our call today. 2024 is off to an impressive start with a solid first quarter performance. We met key commercial milestones with the successful launch of multiple new products worldwide. We outperformed financially, demonstrating a return to growth both in and outside the United States. Operationally, we are continuing to evolve the organization for scalable growth through investments in people, processes and technology.
We are laying the foundation for 2024 to be a transformational year for Tandem, much like when we launched our first automated insulin delivery algorithm approximately 5 years ago. There is growing excitement across our company as we deliver on our strategy to bring greater choice and benefits to people living with diabetes worldwide.
In the first quarter, we executed on expanding our robust portfolio of delivery devices that offer choice and sensor integration, applications and data management tools. Beginning with hardware, we marked another first for our company this quarter. We are now the only manufacturer offering multiple insulin pump form factors....
Read the full article on Seeking Alpha
For further details see:
Tandem Diabetes Care, Inc. (TNDM) Q1 2024 Earnings Call Transcript